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In patients with poorly controlled type 2 diabetes
mellitus (T2DM), hepatic insulin resistance and
increased gluconeogenesis contribute to fasting and
postprandial hyperglycemia. Since cAMP response
element-binding protein (CREB) is a key regulator
of gluconeogenic gene expression, we hypothesized
that decreasing hepatic CREB expression would
reduce fasting hyperglycemia in rodent models of
T2DM. In order to test this hypothesis, we used
a CREB-specific antisense oligonucleotide (ASO) to
knock down CREB expression in liver. CREB ASO
treatment dramatically reduced fasting plasma glu-
cose concentrations in ZDF rats, ob/ob mice, and
an STZ-treated, high-fat-fed rat model of T2DM.
Surprisingly, CREB ASO treatment also decreased
plasma cholesterol and triglyceride concentrations,
as well as hepatic triglyceride content, due to
decreases in hepatic lipogenesis. These results sug-
gest that CREB is an attractive therapeutic target for
correcting both hepatic insulin resistance and dysli-
pidemia associated with nonalcoholic fatty liver
disease (NAFLD) and T2DM.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is strongly associated
with hepatic insulin resistance in patients with poorly controlled
type 2 diabetes mellitus (T2DM) (Petersen et al., 2005; Yki-Jarvi-
nen, 2005). In contrast to our understanding of themechanism of
fat-induced hepatic insulin resistance, the pathogenesis of
increased hepatic gluconeogenesis in T2DM is less well under-
stood. Progressive declines in insulin secretion as well as inap-
propriate increases in glucagon secretion have both been
viewed as critical factors responsible for increased rates of
hepatic gluconeogenesis (Cherrington et al., 1987; ReavenCell Met al., 1987; Unger and Orci, 1977). Glucagon signals through
a canonical G protein-coupled receptor, leading to the activation
of cAMP-dependent protein kinase A (PKA) (Jelinek et al., 1993).
Consequently, PKA phosphorylates Ser133 on cAMP response
element-binding protein (CREB) and causes subsequent translo-
cation to the nucleus (Gonzalez and Montminy, 1989). CREB is a
leucine BH/zipper transcription factor that promotes gene tran-
scription by binding to conserved sequences known as a
cAMP-responsive element (CRE) (Mayr and Montminy, 2001).
CREB is awell-known activator of gluconeogenic gene transcrip-
tion through CREB-binding sites located on promoter regions of
glucose-6-phosphatase (G6Pase), FBPase, and phosphoenol-
pyruvate carboxykinase (PEPCK). Insulin antagonizes the induc-
tion of gluconeogenic enzymes by phosphorylating CREB-
binding protein (CBP) (He et al., 2009; Zhou et al., 2004) and
transducer of regulated CREB activity 2 (TORC2) (Koo et al.,
2005). Thus, CREB is a key nexus where insulin and glucagon
signaling converge on the regulation of hepatic gluconeogenesis.
In the present study, we examined the hypothesis that knock-
down of CREB would blunt the transcriptional actions of glu-
cagon signaling and improve hepatic glucose metabolism in dia-
betic rodent models associated with NAFLD and hepatic insulin
resistance. In order to assess this hypothesis, we knocked down
the expression of CREB in liver and adipose tissue of four
different insulin-resistant rodent models using an antisense
oligonucleotide (ASO) (Samuel et al., 2009). The major advan-
tage of this approach is that it is possible to decrease specific
gene expression in a normal adult animal and avoid the con-
founding compensatory developmental effects often associated
with gene-knockout mouse models.
RESULTS
CREB ASO Decreases Plasma Insulin and Glucose
To achieve a model of mild diabetes, we used an initial strepto-
zotocin (STZ) injection coadministered with a low dose of
nicotinamide. The rats were fed a high-fat diet to induce insulin
resistance. This rat model mimics the pathophysiology of hyper-
glycemia seen in patients with T2DM (Samuel et al., 2009).etabolism 10, 499–506, December 2, 2009 ª2009 Elsevier Inc. 499
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Figure 1. CREB ASO Improves Metabolic Parameters in Three Other Diabetic Models
(A–H) Fasting plasma glucose (A) and insulin (B) concentrations (n = 8–21) in the normal chow and T2DM rat models. Fasting plasma glucose concentrations (C)
were decreased with CREB ASO in the ZDF rat model (n = 4–5). Due to the pancreas-saving effect of lower glucose values, plasma insulin values tended to be
increased (D) (n = 4–5). In the lard-diet-based model, CREB ASO reduced fasting plasma glucose (E) and insulin (F) concentrations (n = 7–9). Lastly, CREB ASO
also reduced fasting plasma glucose in an ob/obmouse model (G) due to reductions in gluconeogenic genes (H) (n = 4–5). *p < 0.05, **p < 0.005. All values are
expressed as the average SEM.Fasting (T2DM: 129 ± 4 mg/dl versus normal: 111 ± 3 mg/dl, p <
0.05) and peak (T2DM: 547 ± 24 mg/dl versus normal: 321 ±
75mg/dl, p < 0.01) glucose concentrations during an intravenous
glucose tolerance test were increased in the T2DM rat model
compared to normal rats fed a standard rodent chow. Despite
their marked hyperglycemia following the intravenous glucose
tolerance test, there was no compensatory hyperinsulinemia as
compared to the normal rats (T2DM: 2626 ± 833 mU-min/ml
versus normal: 2280 ± 372 mU-min/ml, p = NS), which is similar
to what is observed in patients with T2DM (Samuel et al.,
2009).
CREB ASO reduced both CREB mRNA and protein levels in
liver (Figures S1A and S1B) and WAT but not muscle (Table S2).500 Cell Metabolism 10, 499–506, December 2, 2009 ª2009 ElsevieIn normal rats fed a standard rodent chow, CREB ASO treatment
had no effect on fasting plasma glucose concentrations
(Figure 1A) but increased whole-body insulin sensitivity, as
reflected by a 65% reduction in fasting plasma insulin concentra-
tions (Figure 1B). In T2DM rats, CREB ASO treatment decreased
fasting plasma glucose concentrations compared to the control
ASO (Figure 1A). Consistent with our findings in normal rats,
CREB ASO treatment also improved whole-body insulin sensi-
tivity in this T2DM rat model, as reflected by a 66% reduction in
fasting plasma insulin concentrations (Figure 1B). Fasting plasma
glucagon concentrations were similar in both ASO-treated
groups (Table S1). Among the gluconeogenic enzymes and
their key cofactors—cytosolic PEPCK, mitochondrial PEPCK,r Inc.
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Figure 2. CREB ASO Treatment Reduces Hepatic Lipid Content
(A–G) Long-chain acyl-CoAs (A) and liver DAGs (B) were decreased with CREB ASO treatment (n = 8–10). Liver triglycerides were reduced in the fasted and fed
states with CREB ASO (C). In vivo lipogenesis was reduced with CREB ASO, as assessed by the incorporation of [1-14C]palmitate into triglycerides (n = 4 per
group) (D). C/EBPa (E), C/EBPb (F), and key lipogenic genes (G) were assessed by RT-PCR (n = 4–7). *p < 0.05, **p < 0.005 for control ASO versus CREB
ASO; # p < 0.05 for control ASO-fasted versus control ASO-fed. All values are expressed as the average SEM.and the transcriptional coactivator peroxisomal proliferator-acti-
vated receptor gamma coactivator-1a (PGC-1a)—mRNA were
decreased by 43%, 55%, and 54%, respectively, in the liver of
the CREB ASO group (Table S2). Interestingly, there was no
observed difference in catalytic G6Pase and hepatocyte nuclear
factor-4a (HNF-4a), even though the promoter sequences
encoding these genes contain known CREB-binding sites (Table
S2). These data suggest that other transcriptional regulatory
factors independently regulate G6Pase expression.
To verify the results found with CREB ASO in the T2DM rat
model, we used three other models of diabetes. CREB ASO
reduced fasting glucose concentrations by 178 mg/dl in Zucker
Diabetic Fatty (ZDF) rats (Figure 1C), with significant reductions
of CREB in liver but not WAT (Figures S1C and S1D). Plasma
insulin values tended to be increased due to pancreatic sparing
from lower plasma glucose values (Figure 1D) (Harmon et al.,Cell M2001). To complement the studies in our T2DM rat model, we
substituted the safflower oil with a lard-based diet that is high
in hydrogenated fatty acids. Consistent with the other insulin-
resistant rodent models, CREB ASO reversed insulin resistance
in these lard-fed rats, as reflected by decreased fasting plasma
glucose (Figure 1E) and insulin concentrations (Figure 1F). In
addition to the above-mentioned rat models, CREB ASO
also dramatically reduced plasma glucose concentrations by
144 mg/dl in ob/ob mice (Figure 1G), which was associated
with 60% reductions in G6Pase, FBPase, cPEPCK, and pyru-
vate carboxylase mRNA expression (Figure 1H).
CREB ASO Reduces Hepatic Lipid Content in the T2DM
Rat Model
Intrahepatic long-chain coenzymes A (CoAs) and diacylglycerols
(DAGs) were both loweredwith CREBASO treatment (Figures 2Aetabolism 10, 499–506, December 2, 2009 ª2009 Elsevier Inc. 501
Cell Metabolism
CREB ASO Prevents Hepatic Insulin ResistanceA B C
0
1
2
3
4
T2DM Rat Model
*
IR
S
-
2
  
P
h
o
s
p
h
o
t
y
r
o
s
in
e
(
a
r
b
it
r
a
r
y
 u
n
it
s
)
0.0
0.5
1.0
1.5
*
T2DM Rat  Model
M
e
m
b
r
a
n
e
 
P
K
C
e
(
R
e
la
t
iv
e
 t
o
 N
a
-
K
 A
T
P
a
s
e
)
Normal T2DM Rat Model
0
25
50
75
100
125
*
#
Control  ASO
CREB ASO
S
u
p
p
r
e
s
s
io
n
 o
f
 h
e
p
a
t
ic
g
lu
c
o
s
e
 p
r
o
d
u
c
t
io
n
(
%
 o
f
 b
a
s
a
l)
D
0.0
0.5
1.0
1.5
2.0
T2DM Rat  Model
*
*
A
k
t
2
 a
c
t
iv
it
y
(
f
o
ld
 i
n
c
r
e
a
s
e
)
Figure 3. CREB ASO Treatment Improves Hepatic Insulin Sensitivity in T2DM Rats
(A–D) Suppression of hepatic glucose production (A) was assessed using the hyperinsulinemic-euglycemic clamp (n = 4–14 per treatment group). In the T2DM rat
model, CREB ASO reduced membrane PKC3 (B) (n = 4 per treatment group), increased IRS-2 tyrosine phosphorylation (C) (n = 9 per treatment group), and
improved Akt2 activity (D) (n = 5 per treatment group). *p < 0.05 for CREB ASO versus control ASO; # p < 0.05 for T2DM control ASO versus normal chow control
ASO. All values are expressed as the average SEM.and 2B). CREB ASO reduced liver triglyceride content by 57% in
the fasted state. After a meal enriched with fat, liver triglycerides
increased by 76% in the control ASO-treated rats compared to
the fasted state, but did not change in the CREB ASO group
(Figure 2C). To test if in vivo lipogenesis was decreased, we gav-
aged control and CREB ASO T2DM rats with whipping cream
enriched with [1-14C]palmitate to examine the rate of incorpora-
tion of labeled fatty acids into triglycerides. There was a 73%
reduction in the radioactive counts found in hepatic triglycerides
with CREB ASO, reflecting decreased hepatic lipogenesis,
specifically re-esterification (Figure 2D). Both C/EBPa and
C/EBPb have been implicated in the regulation of lipogenesis
(Matsusue et al., 2004; Pedersen et al., 2007; Qiao et al., 2006;
Rahman et al., 2007; Schroeder-Gloeckler et al., 2007) and
have CREB-binding sites when we analyzed the promoter
sequences of these genes (Niehof et al., 1997). We examined
hepatic expression of both of these proteins and found them to
be dramatically reduced with CREB ASO (Figures 2E and 2F).
Consistent with these observations, DGAT2 and mtGPAT
mRNA expression were also decreased, which could explain
the decreased hepatic lipogenesis (Figure 2G).
CREB ASO Increases Hepatic Insulin Sensitivity
and Insulin Signaling
We assessed the effects of decreased liver and adipose CREB
expression on hepatic and peripheral insulin sensitivity using
hyperinsulinemic-euglycemic clamps (Samuel et al., 2007).
Basal hepatic glucose production (Figure S1E) and insulin-stim-
ulated peripheral glucose uptake rates (Figure S1F) were similar
in both rat models and ASO groups. In contrast, hepatic insulin
responsiveness was markedly increased in the CREB ASO-
treated T2DM rat model, as reflected by a 45% increase in sup-
pression of hepatic glucose production during the clamp
compared to the control ASO-treated rats (Figure 3A). Addition-
ally, CREB ASO increased hepatic responsiveness in the lard-
fed rats (Figure S1G). We have previously shown that NAFLD is
associated with accumulation of intracellular DAG content,
leading to increased activation of PKC3 and subsequent reduc-
tion in insulin signaling at the level of insulin receptor substrate 2
(IRS-2) tyrosine phosphorylation (Samuel et al., 2004, 2007).502 Cell Metabolism 10, 499–506, December 2, 2009 ª2009 ElsevConsistent with these studies, we found that CREB ASO treat-
ment reduced hepatic DAG content, which was associated
with lower PKC3 membrane translocation in liver (Figure 3B).
These changes were associated with improved insulin signaling,
as reflected by increased insulin-stimulated IRS-2 tyrosine phos-
phorylation (Figure 3C) and Akt2 activity (Figure 3D). Our results
are in contrast to previous studies that used a dominant-negative
polypeptide A-CREB or Ad-CREB RNAi to knock down the
expression of CREB in primary rat hepatocytes (Canettieri
et al., 2005). While these studies found that it resulted in reduced
expression of IRS-2 (Canettieri et al., 2005), we found no differ-
ences in IRS-2 expression (Table S2) in the CREB ASO-treated
rats compared to the control ASO-treated rats. Regulation of
IRS-2 transcription is complicated and dependent on the fed
and fasted state and multiple transcription factors, which may
explain these discrepancies.
CREB ASO Lowered Plasma Triglycerides
and Cholesterol
CREB ASO treatment decreased plasma triglycerides by 24% in
the T2DM rats (Figure 4A). Total plasma cholesterol and HDL
cholesterol were also decreased in rats treated with CREB ASO
(Table S1). FPLC analysis revealed that the decreases in total
plasma cholesterol could be attributed to significant decreases
in VLDL, LDL, and HDL cholesterol (Figure 4B). Hepatic free
cholesterol was unaltered (Figure 4C), but CREBASOdecreased
hepatic cholesterol esters, as assessed by nuclear magnetic
resonance (NMR) (Figure 4D). Genes relating to cholesterol syn-
thesis, sterol regulatory element-binding protein 2 (SREBP-2),
and hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) were
increased by 50%–60% with CREB ASO treatment (Table S2).
We measured the rate of sterol synthesis in primary rat hepato-
cytes and found no effect of CREB ASO treatment on the incor-
poration rate of [1-14C]acetic acid into cholesterol (Figure 4E).
Additionally, expression of the low-density lipoprotein receptor
(LDLR) and scavenger receptor class B type 1 (SR-B1) were
unaltered with CREB ASO treatment, suggesting that alterations
in cholesterol uptake were not the cause of reduced plasma
cholesterol concentrations (Table S2). Lastly, we looked at the
rate of bile acid synthesis by quantifying the expression ofier Inc.
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Figure 4. CREB ASO Therapy Decreases Plasma Triglycerides and Cholesterol
(A–F) Plasma triglycerides were decreased with CREB ASO (n = 10–12) (A). The lipoprotein profile showed significant reductions in VLDL, LDL, and HDL with
CREB ASO (B). Free hepatic cholesterol was unchanged with CREB ASO (n = 4 per treatment group) (C), but CREB ASO decreased the concentration of hepatic
cholesterol esters (D), as assessed by NMR. Synthesis of cholesterol in rat hepatocytes was assessed by relative [1-14C]acetic acid incorporation into sterols (E)
(n = 3–7 per treatment group). Amount of bile acids extracted from feces during a 12 hr fast is shown in (F) (n = 7 per treatment group). *p < 0.05 for control ASO
versus CREB ASO. All values are expressed as the average SEM.cholesterol 7 alpha-hydroxylase (Cyp7A1). CREBASO treatment
resulted in an approximately 2-fold increase in Cyp7A1 expres-
sion (Table S2). Consistent with the increased expression of
Cyp7A1, fecal bile content was approximately 3-fold higher
compared to control ASO-treated rats (Figure 4F). This suggests
that increased cholesterol export into fecal bile is the most likely
explanation for the reduced plasma cholesterol concentrations
in the CREB ASO-treated rats.
DISCUSSION
These studies found that decreasing hepatic expression of
CREB dramatically improved fasting plasma glucose and insulin
concentrations in three different insulin-resistant rodent models.
In addition, CREB inhibition improved hepatic insulin sensitivity
and reduced plasma glucose concentrations in a T2DM rat
model associated with fatty liver and hepatic insulin resistance.
We found that decreased CREB expression improves hepatic
insulin responsiveness by two mechanisms. First, decreased
expression of CREB led to reduced intrahepatic DAG content
and decreased PKC3 activation (Samuel et al., 2007). Previous
studies have demonstrated that PKC3 binds to the insulin
receptor, leading to reduced insulin receptor-b kinase activity.
Moreover, decreasing expression of PKC3, using a similar
ASO approach, protects rats from fat-induced hepatic insulinCell Mresistance (Samuel et al., 2007). In addition, knockdown of
CREB resulted in reduction of PEPCK and transcriptional gene
cofactors involved in the regulation of hepatic gluconeogenesis.
It is likely that a combination of these two mechanisms contrib-
uted to the decreased glucose production observed in the
CREB ASO-treated rats during the hyperinsulinemic-euglycemic
clamp.
Surprisingly, CREB ASO treatment also decreased hepatic
triglyceride content in the T2DM rat model, which we found
could mostly be ascribed to decreased hepatic lipogenesis.
These findings are in contrast to a previous study, which showed
that dominant-negative CREB-expressing adenovirus indi-
rectly increased expression of peroxisome proliferator-activated
receptor gamma (PPARg) and increased hepatic triglyceride
content independent of SREBP by decreasing expression of
hairy and enhancer of split 1 (HES-1), a transcriptional repressor
of PPARg (Herzig et al., 2003). In our model, we observed no
increase in the level of PPARg expression, possibly reflecting
differences in the models used or the method of knockdown.
We also saw reductions in lipid synthesis, as assessed by incor-
poration of [1-14C]palmitate into hepatic triglycerides indepen-
dent of differences in ChREBP or SREBP1c. Here, we observed
decreased C/EBPa and C/EBPb in the fasted and fed states with
CREB ASO. C/EBPb has been thought to reduce lipogenesis
through PPARg2 (Schroeder-Gloeckler et al., 2007); however,etabolism 10, 499–506, December 2, 2009 ª2009 Elsevier Inc. 503
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expression. Previous reports have indicated that decreases in
C/EBPa are also associated with reductions in lipogenesis
through potentially direct binding to the promoters of key lipo-
genic genes and through controlling upstream lipogenic tran-
scription factors (Matsusue et al., 2004; Qiao et al., 2006). It is
likely that both of these proteins contributed to the decreased
lipogenesis observed with CREB ASO. Immunoneutralization
of glucagon and the glucagon receptor (GCGR) ASO have both
been shown to decrease triglycerides in certain rodent models
(Sloop et al., 2004; Sørensen et al., 2006). The reductions of
lipids in these models could potentially be mediated via reduc-
tions in CREB signaling, since glucagon is upstream of CREB.
A recent study showed that CREB increased expression of
adiponectin through ATF3, resulting in decreased hepatic lipids
(Qi et al., 2009). However, in our study, we found no differences
in plasma adiponectin concentrations. Taken together, these
data suggest that the reduction in hepatic lipogenesis and
improvement in hepatic insulin responsiveness that we observed
in theCREBASO-treated animals ismost likely due to decreased
hepatic expression of CREB and not to alterations in adiponectin
secretion secondary to reductions in CREB expression in adipo-
cytes. This hypothesis is further supported by our studies in the
ZDF T2DM rat model, where we found no reductions in adipose
tissue CREB expression but dramatic reductions in fasting
plasma glucose concentrations.
In summary, this study demonstrates that reduction of CREB
expression in liver and fat lowers plasma triglyceride and choles-
terol concentrations in a T2DM rat model and protects against
fat-induced hepatic steatosis and hepatic insulin resistance by
reductions in PEPCK expression and hepatic diacylglycerols.
Consistent with these results, CREBASOproved to lower fasting
plasma glucose concentrations in four different rodent models of
T2DM and hepatic insulin resistance. This paper is in contrast to
previous literature arguing that hepatic CREB would be a poor
target for pharmacological inhibition (Canettieri et al., 2005; Her-
zig et al., 2003). Since T2DM is often associated with hypertrigly-
ceridemia, hypercholesterolemia associated with NAFLD, and
hepatic insulin resistance, CREB is a potentially attractive thera-
peutic target for T2DM.
EXPERIMENTAL PROCEDURES
Animals
All procedures were approved by the Institutional Animal Care and Use
Committee of Yale University School of Medicine. Male Sprague-Dawley
rats, ZDF rats, or ob/ob mice were received from Charles River Laboratories
(Wilmington, MA) and given 3 days to acclimate. For the T2DM rat model,
rats were then given a 175mg/kg dose of nicotinamide by intraperitoneal injec-
tion; after 15 min, rats were then dosed with a 65 mg/kg dose of STZ (Masiello
et al., 1998). Rats were given 4 days of a recovery period and randomized for
blood glucose values prior to the first ASO injection. Rats with overt diabetes
(defined by a glucose value greater than 200 mg/dl) were excluded from the
study. Rats were housed individually on a 12:12 hr light/dark cycle and
received food and water ad libitum. Body weight and food consumption
were monitored weekly. The food consumed consisted of regular rodent
chow (60% carbohydrate, 10% fat, 30% protein calories); a high-fat diet
(26% carbohydrate, 59% fat, 15% protein calories), in which the major consti-
tute is safflower oil; a high-fat lard diet (24% carbohydrate, 55% fat, 21%
protein), in which the major constitute is hydrogenated vegetable shortening;
or, in the case of the ZDF rats, the Purina Lab Diet 5008.504 Cell Metabolism 10, 499–506, December 2, 2009 ª2009 ElsevieIn Vivo Lipogenesis
Heavy whipping cream (1.8 ml), sucrose (0.6 g; Sigma Aldrich; St. Louis),
normal saline (0.3 ml), and [1-14C]potassium palmitate (30 mCi) dissolved in
0.3 ml EtOH (PerkinElmer; Waltham, MA) were mixed together. The solution
was gavaged into fasted 380 g rats treated with either control ASO or
CREB ASO. Plasma blood samples were taken at 0, 60, 180, and 360 min for
free fatty acid enrichment. Rats were anesthetized with pentobarbital sodium
injection (150 mg/kg), and all tissues were extracted and frozen immediately
with the use of liquid N2-cooled aluminum tongs. Ground liver (100 mg) was
used for triglyceride enrichment and extracted using the method from Bligh
and Dyer (Bligh and Dyer, 1959). The organic layer was evaporated to dryness
and redissolved in 0.5ml chloroform. Twenty-fivemicroliters of the lipid extract
solution was plated on a Silica Gel 60 plate and ran with a 80:20:1 solution of
hexane:diethylether:acetic acid. The plate was dried and developed with
0.005%primuline in 80%acetone inwater. The triglyceride spotswere scraped
off the plate and eluted with diethylether in a glass Pasteur pipette. The dieth-
ylether was evaporated to dryness, and the remaining residuewas dissolved in
0.5 ml hexanes. Fifty microliters of the hexane mixture was measured using
a radioactive scintillation counter to determine total counts.
Hyperinsulinemic-Euglycemic Clamp Studies
Hyperinsulinemic-euglycemic clamps were performed as previously
described (Erion et al., 2009).
Biochemical Analysis and Calculations
Plasma insulin, glucagon, leptin, and adiponectin concentrations were deter-
mined using RIA kits (Linco; Billerica, MA). For FPLC analysis, samples from
control ASO and CREBASOwere pooled together and injected on to an Amer-
shamAKTA FPLC (AmershamPharmacia Biotech/GEHealthcare; Piscataway,
NJ) and eluted at a constant flow rate of 0.5 ml/min FPLC buffer (0.15 M NaCl,
0.01 M Na2HPO4, 0.1 mM EDTA [pH 7.5]).
Tissue Lipid Measurement
The purification and measurements of DAGs and long-chain fatty acyl-CoAs
from liver were performed as previously described (Bligh and Dyer, 1959;
Neschen et al., 2002).
Liver Insulin Signaling
To test the effect of CREB treatment on insulin signaling, rats were treated
exactly the same as described for the T2DM rat model. These rats underwent
a 20 min hyperinsulinemic-euglycemic clamp, and immediately following the
20 min period, the liver was harvested and subsequently frozen with the use
of N2-cooled aluminum tongs. The activity of AKT was assessed bymeasuring
the incorporation of 32P onto a synthetic AKT substrate as previously
described (Choi et al., 2007). PKC3 and IRS-2 blots were performed as previ-
ously described (Choi et al., 2007). Blots were quantified as amount of PKC3
relative to Na-K ATPase located in the membrane fraction (arbitrary units).
Total RNA Preparation, Real-Time Quantitative RT-PCR Analysis,
and Immunoblotting Analysis
PCR was performed as previously described (Erion et al., 2009). For western
blot analysis, 20 mg of powdered tissue was homogenized in 200 ml of homog-
enization buffer (50 mM Tris-HCl buffer [pH 7.5 at 4C], 50 mM NaF, 5 mM
NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol [DTT], 1 mM benzami-
dine, 1 mM phenylmethanesulfonyl fluoride [PMSF], glycerol [10% v/v], Triton
X-100 [1% v/v]). After centrifugation for 15min at 10,000 g, 40 mg crude protein
was added to an equal portion of loading buffer for 5min of 95C heat and then
separated on a 4%–12% gradient polyacrylamide gel in MOPS buffer system
(Invitrogen; Carlsbad, CA). Subsequently, membranes were transferred to
nitrocellulose membranes, and membranes were incubated in blocking buffer
(5%milk) for 1 hr and immunoblotted with anti-CREB antibody (Cell Signaling;
Danvers, MA) overnight. The secondary antibody detection was performed as
previously described (Erion et al., 2009).
Statistical Analysis
All values are expressed as the average SEM. The significance between the
mean values for each study was evaluated by two-tailed unpaired Student’sr Inc.
Cell Metabolism
CREB ASO Prevents Hepatic Insulin Resistancet test or one-way ANOVA followed by post hoc analysis using the Tukey’s Hon-
estly Significant Differences (HSD) test.
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Supplemental References, two tables, and one figure and can be found
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